Skip to main content
SpringerLink
Log in

Vaccinatie tegen humaan papillomavirus

  • Chapter
Anticonceptie

  • 687 Accesses

Abstract

Op 8 juli 2008 heeft de minister van VWS toestemming gegeven om vaccinatie tegen humaan papillomavirus (HPV) op te nemen in het Rijksvaccinatieprogramma. [1] Vanaf september 2009 worden alle meisjes van 12 jaar ingeënt tegen HPV en voor meisjes van 13-16 jaar wordt sinds maart 2009 een inhaalprogramma geadviseerd. De minister heeft dit besluit genomen op basis van het advies van de Gezondheidsraad. [2] De motivering van deze beslissing heeft in Nederland veel reacties van zowel voor- als tegenstanders opgeroepen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatuur

  1. Vaccinatie tegen baarmoederhalskanker. Den Haag: de minister van Volksgezondheid, Welzijn en Sport; 8 juli 2008.

    Google Scholar 

  2. Gezondheidsraad. Vaccinatie tegen baarmoederhalskanker. Den Haag: Gezondheidsraad; 2008. publicatienr. 2008/08.

    Google Scholar 

  3. Kok IMCM de, Habbema JDF, Mourits MJE, Coebergh JWW, Leeuwen FE van. Onvoldoende gronden voor opname van vaccinatie tegen Humaan papillomavirus in het Rijksvaccinatieprogramma. Ned Tijdschr Geneeskd. 2008;152:2001–2004.

    PubMed  Google Scholar 

  4. Boeke AJP. Advies van de Gezondheidsraad om vaccinatie tegen Humaan papillomavirus op te nemen in het Rijksvaccinatieprogramma om baarmoederhalskanker te voorkomen. Ned Tijdschr Geneeskd. 2008;152:981–983.

    CAS  PubMed  Google Scholar 

  5. Rossum TGJ van, Melker HE de, Houweling H, Voordouw ACG, Meijer CJLM, Helmerhorst ThJM, et al. Vaccins tegen Humaan papillomavirus (HPV); tussen registratie en implementatie. Ned Tijdschr Geneeskd. 2008;152:987–992.

    PubMed  Google Scholar 

  6. Noordaa J van der, Houweling H. Gronden voor opname van vaccinatie tegen baarmoederhalskanker in het Rijksvaccinatieprogramma. Ned Tijdschr Geneeskd. 2008;152:2267–2269.

    PubMed  Google Scholar 

  7. Burger MPM. Vaccinatie tegen HPV. NTOG. 2009;122:109–112.

    Google Scholar 

  8. Zielinski GD, Snijders PJ, Rozendaal L, Voorhorst FJ, Linden HC van der, Runsink AP, et al. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer. 2001;85:398–404.

    Article  CAS  PubMed  Google Scholar 

  9. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–65.

    CAS  PubMed  Google Scholar 

  10. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol. 2006;208:152–64.

    Article  CAS  PubMed  Google Scholar 

  11. www.ikcnet.nl/uploaded/FILES/Landelijk/cijfers/incidentie%202006/A01_NL.xls.

  12. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet. 2004;364:1757–65.

    Article  CAS  PubMed  Google Scholar 

  13. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–70.

    Article  CAS  PubMed  Google Scholar 

  14. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27.

    Google Scholar 

  15. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–43.

    Article  CAS  PubMed  Google Scholar 

  16. Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271–78.

    Article  PubMed  Google Scholar 

  17. The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 viruslike- particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet. 2007;369:1861–68.

    Google Scholar 

  18. Tay EH, Garland S, Tang G, Nolan T, Huang LM, Orloski L, et al. Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region. Int J Gynaecol Obstet. 2008;102:275–83.

    Article  CAS  PubMed  Google Scholar 

  19. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006;107:18–27.

    PubMed  Google Scholar 

  20. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus- like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564–71.

    Article  PubMed  Google Scholar 

  21. Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16 en 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007;26:201–09.

    Article  PubMed  Google Scholar 

  22. Productinformatie Cervarix®, via www.emea.europa.eu, human medicines, EPAR's.

  23. EMEA statement on the safety of Gardasil. www.emea.europa.eu/humandocs/PDFs/EPAR/gardasil/Gardasil_press_release.pdf.

  24. CFH-Rapport Gardasil®, via www.cvz.nl, CFH-rapporten.

  25. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–55.

    Article  CAS  PubMed  Google Scholar 

  26. Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen J, Iversen O-E, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459–66.

    Article  CAS  PubMed  Google Scholar 

  27. Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009;20:5 (Epub ahead of print).

    Google Scholar 

  28. www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON028377&RevisionSelection.

  29. Method=Latest. Suspected adverse reactions analysis. CERVARIX human papillomavirus (HPV) vaccine; 21 mei 2009.

    Google Scholar 

  30. www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm165145.htm.

  31. Brotherton JML, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S, et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ. 2008;179:525–33.

    PubMed  Google Scholar 

  32. www.cdc.gov/vaccinesafety/vaers/gardasil.htm, geraadpleegd op 25 mei 2009.

  33. www.uni-bielefeld.de/gesundhw/ag3/downloads/Statement_HPV-vaccine.pdf.

Download references

Authors
  1. Dr. D. Bijl
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Carla van der Wijden

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Bohn Stafleu van Loghum, onderdeel van Springer Uitgeverij

About this chapter

Cite this chapter

Bijl, D. (2010). Vaccinatie tegen humaan papillomavirus. In: van der Wijden, C. (eds) Anticonceptie. Bohn Stafleu van Loghum, Houten. https://doi.org/10.1007/978-90-313-7709-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-90-313-7709-1_2

  • Publisher Name: Bohn Stafleu van Loghum, Houten

  • Print ISBN: 978-90-313-7708-4

  • Online ISBN: 978-90-313-7709-1

  • eBook Packages: Dutch language eBook collection

Publish with us

Policies and ethics

Search

Navigation